

# New York Life Global Funding

# \$40,000,000,000 GLOBAL DEBT ISSUANCE PROGRAM

This supplement ("Second Offering Memorandum Supplement") is supplemental to and must be read in conjunction with the Offering Memorandum, dated March 26, 2025, as supplemented by the First Offering Memorandum Supplement, dated May 23, 2025 (the "Offering Memorandum"), prepared by New York Life Global Funding (the "Issuer") under the Issuer's \$40,000,000,000 Global Debt Issuance Program (the "Program") for the issuance of senior secured medium-term notes (the "Notes").

This Second Offering Memorandum Supplement constitutes a "Base Listing Particulars Supplement" for the purposes of listing on the Official List and trading on the Global Exchange Market. The Irish Stock Exchange Plc, now trading as Euronext Dublin, has approved this Second Offering Memorandum Supplement. References herein to this document are to this Second Offering Memorandum Supplement incorporating Annex 1 hereto.

On August 20, 2025, New York Life Insurance Company ("New York Life") published its interim condensed unaudited financial statements as of June 30, 2025 (including any notes thereto, the "Second Quarter 2025 Financial Statements") and on August 20, 2025 made available New York Life's Summary of Certain Second Quarter Financial Information, Certain Financial and Accounting Matters, Statutory Capitalization of New York Life, and Selected Historical Statutory Financial Information of New York Life (collectively, the "Second Quarter 2025 Financial Information"). Annex 1 to this document sets out the Second Quarter 2025 Financial Information at pages 3 to 24 and the Second Quarter 2025 Financial Statements at pages 25 to 40. Copies of the Second Quarter 2025 Financial Information and the Second Quarter 2025 Financial Statements will be made available for inspection at the offices of the parties at whose offices documents are to be available for inspection as identified in "General Information" in the Offering Memorandum.

Except as disclosed in this document, there has been no other significant new factor, material mistake or inaccuracy relating to the information included in the Offering Memorandum, nor has there been any significant change in the financial or trading position of New York Life since June 30, 2025 (the date of the Second Quarter 2025 Financial Statements).

Each of the Issuer and New York Life accepts responsibility for the information contained in this Second Offering Memorandum Supplement. To the best of the knowledge of each of the Issuer and New York Life (having taken all reasonable care to ensure that such is the case) the information contained in this Second Offering Memorandum Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Where there is any inconsistency among the Offering Memorandum and this Second Offering Memorandum Supplement, the language used in this Second Offering Memorandum Supplement shall prevail.

Second Offering Memorandum Supplement dated August 20, 2025

# ANNEX 1

# SUMMARY OF CERTAIN SECOND QUARTER FINANCIAL INFORMATION

Results of Operations – For the Six Months Ended June 30, 2025 Compared to the Six Months Ended June 30, 2024

*Net Income/(Loss)* 

New York Life's net loss, which is comprised of net gain/(loss) from operations after dividends to policyholders and federal and foreign income taxes plus net realized capital gains (losses) (after-tax and transfers to the interest maintenance reserve ("IMR")), was \$286 million for the six months ended June 30, 2025, representing a \$1,054 million decrease compared to net income of \$768 million reported for the six months ended June 30, 2024. The decrease in net income year-over-year was primarily driven by an \$848 million decline in net gain from operations after dividends and taxes, along with a \$206 million increase in realized capital losses for the six months ended June 30, 2025.

# Net Gain from Operations

As a mutual insurance company, all dividends paid by New York Life to participating policyholders are included in net gain from operations. However, since dividends are supported by unassigned surplus, not all of the sources that support dividends are reported in pre-dividend net gain (such as capital gains (losses) and undistributed earnings from subsidiaries). Therefore, focusing on net gain from operations before dividends to policyholders and federal and foreign income taxes provides the best insight into New York Life's performance.

Net gain from operations before dividends to policyholders and federal and foreign income taxes for the six months ended June 30, 2025 was \$1,249 million, representing a decrease of \$719 million, or 37%, when compared to the net gain from operations before dividends to policyholders and federal and foreign income taxes of \$1,968 million reported for the six months ended June 30, 2024. While results reflect higher bond income, driven by both higher yields and increased average invested assets, and lower operating expenses, the year-over-year decrease was primarily driven by lower U.S. insurance subsidiary dividends (see "—Net Investment Income (including amortization of IMR)" and "—Operating Expenses").

Dividends to policyholders and federal and foreign income tax benefit for the six months ended June 30, 2025 were \$1,405 million and \$50 million, respectively, and for the six months ended June 30, 2024 were \$1,259 million and \$33 million, respectively (see "—Dividends to Policyholders" and "—Federal and Foreign Income Taxes").

Net (loss) gain from operations after dividends to policyholders and federal and foreign income taxes was \$(106) million and \$742 million for the six months ended June 30, 2025 and 2024, respectively.

### Premium Income

Premium income is primarily generated from sales of life insurance, annuities, long-term care ("LTC") insurance and disability insurance. In addition, sales of Institutional Annuities, with annuity purchase rate guarantees, are considered premium income since there is mortality risk in these products.

Premium income from the insurance business primarily consists of recurring premiums from New York Life's agency sold life insurance business, while premium income from the annuities business is generally single premium and can be more volatile from year to year.

The following table shows premium income by business operation for the six months ended June 30, 2025 and 2024 (\$ in millions):

			Chang	ge
	 2025	2024	\$	%
Life Insurance Solutions	\$ 5,047 \$	4,941 \$	106	2 %
New York Life Direct	821	808	13	2
Group Membership	308	312	(4)	(1)
LTC	199	194	5	3
Closed Block Reinsurance	59	57	2	4
Individual Disability Insurance	 2	1	1	100
Total Insurance Business <sup>1</sup>	6,436	6,313	123	2
Institutional Annuities	 2,968	1,878	1,090	58
Retail Annuities	 431	508	(77)	(15)
Total Annuities Business	3,399	2,386	1,013	42
Total	\$ 9,835 \$	8,699 \$	1,136	13 %

<sup>1</sup> Recurring premiums account for 82% of the total insurance business for the six months ended June 30, 2025 and 2024, respectively.

Life Insurance Solutions premiums for the six months ended June 30, 2025 increased \$106 million compared to the six months ended June 30, 2024, primarily due to higher paid up additions on whole life products.

Institutional Annuities premiums for the six months ended June 30, 2025 increased \$1,090 million compared to the six months ended June 30, 2024, primarily due to higher sales of stable value products.

Retail Annuities premiums for the six months ended June 30, 2025 decreased \$77 million compared to the six months ended June 30, 2024, primarily due to lower sales of participating income annuities.

Net Investment Income (including amortization of IMR)

The following table shows investment income based on components of New York Life's investment portfolio for the six months ended June 30, 2025 and 2024 (\$ in millions):

				Chang	ge
	2025	2024		\$	%
Bonds	\$ 3,397 \$	\$ 3,077	\$	320	10 %
U.S. Insurance Subsidiary Dividends <sup>1</sup>	_	890		(890)	(100)
Mortgage Loans	586	497		89	18
Policy Loans	381	377		4	1
Other Invested Assets	151	186		(35)	(19)
Real Estate	210	219		(9)	(4)
Equity Securities	16	13		3	23
Other	137	144		(7)	(5)
Gross Investment Income	4,878	5,403		(525)	(10)
Investment Expenses <sup>2</sup>	(465)	(480)	)	15	3
Net Investment Income	4,413	4,923		(510)	(10)
Amortization of IMR	12	8		4	50
Total	\$ 4,425 \$	4,931	\$	(506)	(10)%

Dividends from the wholly owned U.S. insurance subsidiaries of New York Life. The timing of dividends from New York Life's subsidiaries may vary from year to year and the amount of dividends received can vary subject to the capital needs of the subsidiaries as well as regulatory requirements for the payment of dividends by New York Life's insurance company subsidiaries.

Net investment income for six months ended June 30, 2025 decreased \$506 million compared to the six months ended June 30, 2024, primarily due to lower U.S. insurance subsidiary dividends. This was partially offset by higher bond income, driven by both increased average invested assets and improved yields.

### Other Income

The following table shows the primary components of other income for the six months ended June 30, 2025 and 2024 (\$ in millions):

		_	Chang	e
	2025	2024	\$	%
Investment in COLI policies	\$ 114 \$	133	\$ (19)	(14)%
Commission and expense allowance on reinsurance ceded	72	64	8	13
Net loss on derivatives hedging funding agreements	(91)	(90)	(1)	(1)
Other	21	29	(8)	(28)
Total	\$ 116 \$	136	\$ (20)	(15)%

New York Life has purchased various corporate-owned life insurance ("COLI") policies from New York Life Insurance and Annuity Corporation ("NYLIAC") for the purpose of informally funding non-qualified pension and post-retirement plans and deferred compensation plans. NYLIAC holds the assets supporting these policies.

<sup>2</sup> Investment expenses include interest expense on surplus notes.

Income from these policies represents the net change in cash surrender value, driven by the performance of the underlying assets supporting the policies. The income from the investment in COLI policies during the six months ended June 30, 2025 was lower compared to the six months ended June 30, 2024, largely due to lower equity returns in 2025. This was primarily passed on to participants in certain deferred compensation plans, and therefore was partially offset by lower interest credited expense included in general operating expenses (see "—Operating Expenses").

Commission and expense allowance on reinsurance ceded for the six months ended June 30, 2025 increased \$8 million compared to the six months ended June 30, 2024, primarily due to amortization of the deferred gain from surplus in 2025 related to the Term Reinsurance Agreement and ongoing policy administration charges (see "Certain Financial and Accounting Matters—Reinsurance").

Other income also includes the net loss on settlement of derivatives that hedge either foreign exchange exposure on foreign denominated funding agreements or manage interest rate risk on funding agreements issued under the Program. Although these derivatives generated losses, their financial impact was largely offset by either lower benefit payments in Institutional Annuities due to foreign exchange on benefit payments or higher net investment income earned on floating rate assets as interest rates rose (see "—Net Investment Income (including amortization of IMR)" and "—Benefit Payments").

# Benefit Payments

New York Life's benefit payments primarily include death benefits, annuity benefits, LTC benefits, disability benefits, surrender benefits (including scheduled maturities and withdrawals on Institutional Annuities) and interest on policy claims and deposit funds.

The following table shows benefit payments by business operation for the six months ended June 30, 2025 and 2024 (\$ in millions):

			_	Chan	ige
		2025	2024	\$	%
Life Insurance Solutions	\$	2,863 \$	2,786 \$	77	3 %
New York Life Direct		548	523	25	5
Group Membership		186	203	(17)	(8)
LTC		99	88	11	13
Closed Block Reinsurance		205	197	8	4
Total Insurance Business		3,901	3,797	104	3
Institutional Annuities		5,145	3,796	1,349	36
Retail Annuities		80	68	12	18
Total Annuities Business		5,225	3,864	1,361	35
Total	\$	9,126 \$	7,661 \$	1,465	19 %

Life Insurance Solutions benefit payments for the six months ended June 30, 2025 increased \$77 million compared to the six months ended June 30, 2024, primarily driven by higher surrenders on whole life products as lapse rates normalize to pre-pandemic levels.

Institutional Annuities benefit payments for the six months ended June 30, 2025 increased \$1,349 million compared to the six months ended June 30, 2024, primarily driven by higher withdrawals related to the rebalancing of New York Life's Defined Benefit Pension Plans ("Pension Plans") (see "—Net Transfers to (from) Separate Accounts"), as well as scheduled maturities for guaranteed investment contracts ("GICs") and funding agreements.

### Additions to Reserves

The following table shows additions to reserves by business operation for the six months ended June 30, 2025 and 2024 (\$ in millions):

		<u> </u>	Chang	e
	2025	2024	\$	%
Life Insurance Solutions	\$ 2,590 \$	2,486 \$	104	4 %
New York Life Direct	53	59	(6)	(10)
Group Membership	8	_	8	nm
LTC	148	150	(2)	(1)
Closed Block Reinsurance	(118)	(99)	(19)	(19)
Individual Disability Insurance	 1	_	1	nm
Total Insurance Business	2,682	2,596	86	3
Institutional Annuities	(99)	(40)	(59)	(148)
Retail Annuities	355	409	(54)	(13)
Total Annuities Business	256	369	(113)	(31)
Total	\$ 2,938 \$	2,965 \$	(27)	(1)%

nm = not meaningful

Life Insurance Solutions additions to reserves for the six months ended June 30, 2025 increased \$104 million compared to the six months ended June 30, 2024, primarily due to higher paid up additions on whole life products.

Institutional Annuities additions to reserves for the six months ended June 30, 2025 decreased \$59 million compared to the six months ended June 30, 2024, primarily driven by lower net flows on GICs, partially offset by higher net flows into stable value products.

Retail Annuities additions to reserves for the six months ended June 30, 2025 decreased \$54 million compared to the six months ended June 30, 2024, primarily due to lower sales of participating income annuities.

Net Transfers to (from) Separate Accounts

New York Life's transfers to separate accounts reflect policyholder premium payments. New York Life's transfers from separate accounts reflect benefit payments or fund transfers between the separate accounts and the general account during the reporting period (see "Certain Financial and Accounting Matters—Separate Accounts").

The following table shows the components of the net transfers to (from) separate accounts for the six months ended June 30, 2025 and 2024 (\$ in millions):

		_		Cha	nge
	2025	2024	\$	}	%
Transfers to separate accounts	\$ 1,346 \$	884 5	5	462	52 %
Transfers from separate accounts	(2,048)	(1,601)		(447)	(28)
Total	\$ (702) \$	(717) \$	5	15	2 %

Transfers to separate accounts for the six months ended June 30, 2025 increased \$462 million compared to the six months ended June 30, 2024, primarily related to higher premiums into separate account stable value products. Transfers from separate accounts for the six months ended June 30, 2025 increased \$447 million compared to the six months ended June 30, 2024, primarily due to higher transfers to the general account due to rebalancing within the

Pension Plans separate account contracts, partially offset by lower withdrawals from separate account stable value products (see "—Premium Income" and "—Additions to Reserves").

### Adjustments in Funds Withheld

New York Life at times enters into reinsurance agreements to coinsure its liabilities with other insurers, under which New York Life may retain the assets supporting the reinsured liabilities and establish a corresponding funds withheld liability. The adjustments in funds withheld generally represents the establishment of the funds withheld liability and related interest. Adjustments in funds withheld was \$68 million and \$71 million for the six months ended June 30, 2025 and 2024, respectively, which was related to interest credited on reinsurance agreements (see "Certain Financial and Accounting Matters—Reinsurance").

# Operating Expenses

The following table shows the components of operating expenses for the six months ended June 30, 2025 and 2024 (\$ in millions):

			Chang	e
	2025	2024	\$	%
General operating expenses <sup>1</sup>	\$ 1,347	\$ 1,447	\$ (100)	(7)%
Variable sales expenses <sup>2</sup>	349	371	(22)	(6)
Total	\$ 1,696	\$ 1,818	\$ (122)	(7)%

<sup>1</sup> General operating expenses include, but are not limited to, salaries, incentive compensation, licenses and fees, charitable contributions and rent expense.

General operating expenses for the six months ended June 30, 2025 decreased \$100 million compared to the six months ended June 30, 2024, primarily driven by lower post-retirement expenses due to an increase in assumed discount rates for New York Life's pension and other post-retirement plans and a post-retirement health plan amendment. Additionally, the decrease in general operating expenses was driven by lower interest crediting expense on deferred compensation plans due to lower equity returns, which was partially offset by a decrease in income on investment in COLI policies (see "—Other Income").

### Dividends to Policyholders

The following table shows dividends to policyholders for the six months ended June 30, 2025 and 2024 (\$ in millions):

		_	Chan	ge
	 2025	2024	\$	%
Dividends - New York Life policyholders	\$ 1,384	\$ 1,244	\$ 140	11 %
Dividends - Closed Block Reinsurance <sup>1</sup>	 21	15	6	40
Total	\$ 1,405	\$ 1,259	\$ 146	12 %

<sup>1</sup> Dividends for the Closed Block Reinsurance are approved by the ceding company.

Dividends to New York Life policyholders are approved by New York Life's board of directors (the "**Board** of **Directors**") annually and primarily factor in investment experience (interest earnings, credit loss experience and

<sup>2</sup> Variable sales expenses include agents' commissions and premium tax expense.

equity returns), mortality results and expense levels that develop over a period of time (see "Certain Financial and Accounting Matters—Dividends to Policyholders").

### Federal and Foreign Income Taxes

In accordance with Statutory Accounting Principles ("SAP"), prescribed or permitted by the New York State Department of Financial Services (the "NYSDFS"), current federal and foreign income taxes are reflected in net income, whereas deferred tax items are reflected as a component of surplus. Therefore, differences between the statutory tax rate and book income to tax expense includes temporary book/tax differences in addition to permanent differences. The following table reconciles the tax expense calculated at the statutory rate to the tax benefit reflected in New York Life's results of operations for the six months ended June 30, 2025 and 2024 (in millions):

	 2025	2024	Change
Tax (benefit)/expense on net gain/(loss) from operations	\$ (33) \$	149 \$	(182)
Dividends from subsidiaries <sup>1</sup>	_	(187)	187
Compensation and benefits accrual	(44)	(29)	(15)
Tax credits <sup>2</sup>	(52)	(45)	(7)
Tax exempt income	(41)	(45)	4
Excess of book over tax reserves	72	82	(10)
Deferred acquisition costs tax	26	18	8
Non-deductible pension and post-retirement benefits	6	13	(7)
Other <sup>3</sup>	 16	11	5
Total federal and foreign income tax benefit	\$ (50) \$	(33) \$	(17)

Dividends from subsidiaries represent after-tax earnings of the subsidiaries and are not subject to tax when received by New York Life.

The One Big Beautiful Bill Act (the "Act") was enacted on July 4, 2025. New York Life is currently evaluating the impacts of the Act and does not anticipate any material impact on the company's surplus position as a result of the Act.

<sup>2</sup> Tax credits result primarily from investments in low-income housing and alternative energy.

<sup>3</sup> Other consists mostly of changes in accruals and partnerships.

### Net Realized Capital Gains/(Losses)

New York Life reported net realized capital (losses) after taxes and transfers to the IMR of \$(180) million for the six months ended June 30, 2025, reflecting a decline of \$206 million compared to net realized capital gains of \$26 million reported for the six months ended June 30, 2024.

The following table represents net realized capital gains (losses) for the six months ended June 30, 2025 and 2024 (in millions):

	2025	2024	Change
Bonds	\$ 42 \$	(166) \$	208
Derivatives	(55)	(236)	181
Real estate		191	(191)
Common and preferred stocks	85	25	60
Limited partnerships	(89)	9	(98)
Other <sup>1</sup>	9	_	9
Total before OTTI and capital gains (losses) tax	(8)	(177)	169
OTTI <sup>2</sup>	(140)	(131)	(9)
Capital gains tax expense	(11)	(3)	(8)
Net realized capital losses after-tax and before transfers to the IMR	(159)	(311)	152
Capital (gains) losses transferred to the IMR <sup>3</sup>	(21)	337	(358)
Net realized capital gains (losses) after-tax	\$ (180) \$	26 \$	(206)

<sup>1</sup> Other includes foreign exchange gains and losses on funding agreements related to the Issuer's Notes.

Realized capital gains on bonds of \$42 million for the six months ended June 30, 2025 were primarily due to sales of corporate bonds, specifically an investment-grade bond exchange-traded fund ("ETF") that provides broader exposure to the corporate bond market, as well as corporate foreign agency bonds. The majority of these gains were transferred to the IMR. Realized capital losses on bonds of \$166 million for the six months ended June 30, 2024 were primarily due to sales of U.S. Treasury notes, bond ETFs, and corporate bonds. The majority of these losses were also transferred to the IMR.

Realized capital losses on derivatives of \$55 million for the six months ended June 30, 2025 were primarily due to maturities of derivatives used to hedge foreign-denominated limited partnership ("LP") investments, as the U.S. dollar weakened and LP investment results are reported on a one-quarter lag, preventing offsetting gains from being recognized in the same period. Of this amount, \$15 million was transferred to the IMR for the six months ended June 30, 2025.

Realized capital losses on derivatives of \$236 million for the six months ended June 30, 2024 were primarily driven by the termination of derivative strategies used to hedge against a low-interest rate environment. Of this amount, \$252 million was transferred to the IMR. The losses that will amortize through the IMR are expected to be significantly offset by higher net investment income due to reinvestment at higher interest rates.

Realized capital gains on real estate of \$191 million for the six months ended June 30, 2024 were primarily due to the sale of five properties in the multifamily and industry sectors.

<sup>2</sup> OTTI losses are generally not subject to current tax treatment; however, current year tax includes benefits on current year OTTI on residential mortgage-backed securities and sales of other securities impaired in prior years.

<sup>3</sup> Capital gains tax expense/(benefit) transferred to the IMR was \$6 million and \$(90) million for the six months ended June 30, 2025 and 2024, respectively.

Realized capital gains on common and preferred stocks of \$85 million for the six months ended June 30, 2025 were primarily due to the sale of ETFs tracking the S&P 500 Index and the disposition of New York Life's remaining shares in Max Financial Services Ltd. Realized capital gains on common and preferred stocks of \$25 million for the six months ended June 30, 2024 were primarily due to partial sale of Max Financial Services Ltd.

Realized capital losses on LP interests of \$89 million for the six months ended June 30, 2025 were primarily due to the sale of two properties held within NYLIFE Office Holdings, an LP vehicle used for commercial real estate investments.

The following table shows the distribution of OTTI and the year-over-year change in OTTI by asset type for the six months ended June 30, 2025 and 2024 (in millions):

2025	5	2024	Change
\$	(26) \$	(26) \$	_
	(81)	(58)	(23)
	(20)		(20)
	(4)	(2)	(2)
	(3)	(24)	21
	(6)	(21)	15
\$	(140) \$	(131) \$	(9)
	\$	(81) (20) (4) (3) (6)	\$ (26) \$ (26) \$ (81) (58) (20) — (4) (2) (3) (24) (6) (21)

OTTI on bonds of \$26 million for the six months ended June 30, 2025 was primarily related to a corporate bond in the cable & media sector facing stress from elevated interest rates, ongoing declines in traditional cable TV subscriptions, and heightened competition. Additionally, there was a retail loss attributable to one issuer, which has been impacted by supply chain disruptions and declining demand. OTTI on bonds of \$26 million for the six months ended June 30, 2024 was primarily due to impairments in the healthcare, paper and packaging, chemical, cable and media sectors.

OTTI for LPs was \$81 million and \$58 million for the six months ended June 30, 2025 and 2024, respectively. In both periods, OTTI was primarily driven by leveraged buyouts approaching the end of their lifecycle. In 2025, additional OTTI was recognized related to two real estate office sector LPs impacted by remote and hybrid work trends. Certain LPs record expenses and fees accumulated over the life of the partnership as unrealized losses. Therefore, when the partnership is at the end of its lifecycle such losses are realized and recorded as OTTI.

OTTI on real estate of \$20 million for the six months ended June 30, 2025 was primarily due to an office building with low occupancy.

OTTI on mortgage loans of \$24 million for the six months ended June 30, 2024 was primarily due to impairments in the office sector.

OTTI on other invested assets of \$21 million for the six months ended June 30, 2024 was primarily due to asset backed securities backed by underperforming unsecured consumer loans.

# Financial Position - At June 30, 2025 Compared to December 31, 2024

Assets

New York Life's total assets at June 30, 2025 were \$251,980 million, which was \$7,079 million, or 3%, higher than the \$244,901 million reported at December 31, 2024. The increase was primarily reflected in the following assets:

• \$6,931 million higher cash and invested assets primarily driven by the investment of operating cash flow with the increase primarily in fixed income investments.

### Liabilities

New York Life's total liabilities, including Asset Valuation Reserve ("AVR"), at June 30, 2025 were \$226,298 million, which was \$7,824 million, or 4%, higher than the \$218,474 million reported at December 31, 2024. The increase is primarily reflected in the following liabilities:

• \$8,748 million increase in policy reserves and deposit funds is primarily driven by higher deposits in funding agreements related to issuances of Notes under the Program and Federal Home Loan Bank funding agreements as well as growth and aging of the inforce, particularly in whole life products. The table below presents policy reserves and deposit funds by business operation at June 30, 2025 and December 31, 2024 (\$ in millions):

			Chang	ıge	
	2025	2024	\$	%	
Life Insurance Solutions	\$ 98,973 \$	96,432 \$	2,541	3 %	
New York Life Direct	3,741	3,691	50	1	
Group Membership	2,155	2,133	22	1	
LTC	4,921	4,773	148	3	
Closed Block Reinsurance	4,191	4,322	(131)	(3)	
Individual Disability Insurance	 4	3	1	_	
Total Insurance Business	113,985	111,354	2,631	2	
Institutional Annuities	77,095	71,333	5,762	8	
Retail Annuities	 4,363	4,008	355	9	
Total Annuities Business	81,458	75,341	6,117	8	
Total	\$ 195,443 \$	186,695 \$	8,748	5 %	

# Statutory Surplus

Statutory surplus was \$25,682 million at June 30, 2025, a decrease of \$745 million, or 3%, compared to the \$26,427 million reported at December 31, 2024. The main drivers of the change in New York Life's statutory surplus are presented in the following table (in millions):

	2025
Beginning surplus	\$ 26,427
Net loss	(286)
Change in net unrealized capital gains/(losses) <sup>1</sup>	(6)
Change in deferred taxes <sup>1,2</sup>	(6)
Change in AVR	(161)
Change in nonadmitted assets <sup>2,3</sup>	(273)
Pension and post-retirement impacts <sup>3</sup>	17
Change in surplus as a result of reinsurance	(33)
Other	 3
Ending surplus	 25,682
AVR	4,748
Surplus and AVR <sup>4</sup>	\$ 30,430

<sup>1</sup> Deferred tax benefit on change in net unrealized capital losses of \$53 million was reclassified to "Change in deferred taxes."

<sup>2</sup> An increase in nonadmitted deferred income taxes of \$183 million was reclassified to "Change in deferred taxes."

<sup>3</sup> A decrease in nonadmitted prepaid pension assets of \$49 million was reclassified to "Pension and post-retirement impacts."

<sup>4</sup> Consolidated statutory surplus and AVR, which includes the AVR of New York Life's wholly owned U.S. insurance subsidiaries totaled \$32,785 million at June 30, 2025.

### Change in Net Unrealized Capital Gains/(Losses)

The following table shows the components of the change in net unrealized capital gains/(losses) at June 30, 2025 compared to December 31, 2024 (in millions):

	2025
Affiliated:	
Domestic insurance subsidiaries:	
Operations	\$ (26)
Amortization of goodwill <sup>1</sup>	 (209)
Total domestic insurance subsidiaries	(235)
Asset management subsidiaries	270
Insurance subsidiary in Mexico and other	 212
Total affiliated	247
Unaffiliated:	
Common stocks	(64)
Other invested assets	97
Mortgage Loans	(13)
Other	 (273)
Total unaffiliated	(253)
Total change in net unrealized capital gains/(losses)	\$ (6)

<sup>1</sup> Goodwill associated with the acquisition of New York Life Group Benefit Solutions ("GBS") in 2020.

The \$26 million decrease in net unrealized capital gains related to domestic insurance operations was primarily driven by NYLIAC's derivatives activity. This included mark-to-market losses from the asset/liability duration management program, which is designed to manage interest rate risk and was negatively impacted by a steepening yield curve, as long-term rates rose more than short-term rates. These losses were mostly offset by favorable performance in Life Insurance Company of North America, largely reflecting strong underwriting margins.

The \$273 million decrease in net unrealized capital gains associated with other investments was primarily driven by New York Life's derivatives activity. This included mark-to-market losses from the asset/liability duration management program, which is designed to manage interest rate risk and was negatively impacted by a steepening yield curve, as long-term rates rose more than short-term rates. Additionally, there were mark-to-market losses on derivatives used to hedge foreign-denominated LPs, as the U.S. dollar weakened and LP investment results are reported on a one-quarter lag, preventing offsetting gains from being recognized in the same period.

### Change in Deferred Taxes

The following table shows the components of the change in deferred taxes at June 30, 2025 compared to December 31, 2024 (in millions):

	 2025
Deferred income tax benefit on operating results	\$ 124
Deferred tax benefit on change in net unrealized capital losses	 53
Subtotal	177
Increase in nonadmitted deferred income taxes	 (183)
Total change in deferred taxes	\$ (6)

### Change in AVR

The AVR liability represents a portion of New York Life's surplus set aside to offset potential non-interest related investment losses. Changes in the AVR are recorded directly to surplus. The AVR liability is based on a formula prescribed by the National Association of Insurance Commissioners (the "NAIC") and is largely influenced by the size and quality of the investment portfolio. Changes in the AVR are driven by non-interest related gains and losses on the investment portfolio and an annual contribution based on factors set by the NAIC. Factors are also used to set a reserve objective and a maximum reserve. The AVR liability increased by \$161 million at June 30, 2025 compared to December 31, 2024, which reduced surplus and is currently at its maximum reserve.

### Change in Nonadmitted Assets

Certain assets are not allowed as admitted assets in accordance with SAP. Generally, these are assets with economic value, but which cannot be readily used to pay policyholder obligations. New York Life had a net increase in nonadmitted assets that resulted in a decrease to surplus of \$273 million during the six months ended June 30, 2025. The increase was primarily due to the change in nonadmitted assets related to furniture and equipment and the change in nonadmitted investment in two wholly owned subsidiaries, NYL Investors LLC and Seguros Monterrey, that are included in change in net unrealized gains/(losses). This was partially offset by the change in nonadmitted goodwill associated with the GBS acquisition as a result of the amortization of goodwill that is included in change in net unrealized gains/(losses) (see "—Change in Net Unrealized Capital Gains/(Losses)").

### Pension and Post-retirement Impacts

The calculation of pension and other post-retirement benefits obligations requires management to select demographic and economic assumptions that affect the reported amounts of assets and liabilities at December 31 of each year. Assumptions include, but are not limited to, interest rates, return on plan assets, mortality, withdrawal and retirement rates, and healthcare cost trend rate. The selected actuarial assumptions comply with the NAIC guidance, which requires New York Life to use its best estimate for each assumption, and are reviewed regularly for reasonableness, comparing assumed results to actual plan experience with adjustments made when necessary. New York Life uses a December 31 measurement date for these plans, as required.

Pension and post-retirement related impacts reported as a direct adjustment to surplus do not include the expenses (annual service costs, amortization of unrecognized actuarial losses and prior service costs/(credits)) reported in net gain/(loss) from operations. These adjustments increased surplus by \$17 million.

# **Liquidity Sources and Requirements**

Liquidity Sources

New York Life's cash inflows from its insurance activities include life insurance premiums, annuity considerations, funding agreements, GICs and deposit funds. New York Life's cash inflows from investments result from proceeds on sales, interest payments, repayments of principal, maturities of invested assets and investment income. The following table sets forth the total available liquidity of New York Life from liquid assets and other funding sources at the end of the specified periods (in millions). Liquid assets include cash and cash equivalents, short-term investments and publicly traded securities, excluding assets that are pledged or otherwise committed. Other funding sources includes the available capacity at short-term borrowing facilities.

# New York Life's Available Liquidity at Market Value (in millions)

	June 30, 2025	<b>December 31, 2024</b>
Cash and short-term investments:	,	<u> </u>
Cash and cash equivalents	\$ 2,598	\$ 3,960
Short-term investments	1,019	621
Less: securities lending and other short-term liabilities	 (1,844)	(1,829)
Net cash and short-term investments	1,773	2,752
Liquid bonds:		
U.S. government and agency bonds	4,901	5,504
Public corporate investment-grade bonds & collateralized mortgage obligations	58,420	57,554
Liquid bonds	 63,321	63,058
<b>Equities:</b>		
Public equities	 311	350
Total liquid assets	 65,405	66,160
Other funding sources:		
Bank facility/commercial paper capacity	3,000	3,000
Federal Home Loan Bank available capacity <sup>1</sup>	 8,791	8,514
Total other funding sources	 11,791	11,514
Total available liquidity	\$ 77,196	\$ 77,674

Available capacity represents 5% of New York Life's total admitted assets. At June 30, 2025, New York Life's borrowing capacity with the Federal Home Loan Bank of New York was \$12,599 million, of which \$3,808 million had been used. At December 31, 2024, New York Life's borrowing capacity with the Federal Home Loan Bank of New York Life was \$12,245 million, of which \$3,731 million had been used.

New York Life's U.S. insurance subsidiaries are subject to certain insurance department regulatory restrictions as to the payment of dividends to New York Life. These restrictions pose no short-term or long-term liquidity concerns for New York Life, as it does not rely on subsidiary dividends as a significant source of liquidity.

### Liquidity Uses

New York Life's principal cash outflows primarily relate to the payment of liabilities associated with its various life insurance, annuity and group pension (GICs and funding agreements) products, operating expenses and income taxes. Liabilities arising from New York Life's insurance activities primarily relate to benefit payments, policy surrenders, withdrawals from GICs and maturities of funding agreements, and loans and dividends to policyholders. See "Management's Discussion and Analysis of Financial Condition and Results of Operations—Investment Risk Management" for a discussion of liquidity risk.

A primary liquidity concern with respect to life insurance and annuity products is the risk of early policyholder and contract holder withdrawals. New York Life includes provisions in certain of its contracts that are designed to limit withdrawals from general account institutional pension products (group annuities, GICs and certain deposit fund liabilities) sold to employee benefit plan sponsors. Such provisions include surrender charges, market value adjustments and prohibitions or restrictions on withdrawals. New York Life closely monitors its liquidity requirements in order to match cash inflows with expected cash outflows and employs an asset/liability management approach tailored to the specific requirements of each product line based upon the return objectives, risk tolerance, liquidity, tax and regulatory requirements of the underlying products. It also regularly conducts liquidity stress tests and monitors early warning indicators of potential liquidity issues.

New York Life participates in a securities lending program for its general account whereby fixed income securities are loaned to third parties, primarily major brokerage firms and commercial banks. The borrowers of its securities provide New York Life with collateral, typically in cash. New York Life separately manages this collateral and invests such cash collateral in a portfolio of highly rated fixed income securities with short maturities. Securities on loan under the program could be returned to New York Life by the borrowers, or New York Life could call such securities at any time. Returns of loaned securities would require New York Life to return the cash collateral associated with such loaned securities. New York Life was liable for cash collateral under its control of \$569 million at June 30, 2025 and \$685 million at December 31, 2024. See "Risk Factors—Risk Factors Relating to New York Life—New York Life's Securities Lending Program Subjects It to Potential Liquidity and Other Risks."

New York Life is committed to maintaining adequate capitalization for its insurance and non-insurance subsidiaries to fund growth opportunities and support new products, and, with respect to its U.S. insurance subsidiaries, to maintain targeted risk-based capital ("RBC") levels. In addition, New York Life may make loans to its affiliates to provide additional funds to meet the business needs of these entities. New York Life made capital contributions (net of returns of capital) of \$75 million to its insurance subsidiaries during the six months ended June 30, 2025, and received returns of capital (net of capital contributions) of \$287 million from its insurance and non-insurance subsidiaries during the year ended December 31, 2024.

# CERTAIN FINANCIAL AND ACCOUNTING MATTERS

# **Accounting Policies and Principles**

Statutory Accounting Practices

The financial statements of New York Life included in this Offering Memorandum are presented in accordance with SAP prescribed or permitted by the NYSDFS. SAP differs from generally accepted accounting principles in the United States ("GAAP") in that SAP is primarily designed to reflect the ability of the insurer to satisfy its obligations to policyholders, contract holders and beneficiaries, whereas in accordance with GAAP, revenues and expenses are recorded in financial reporting periods to match revenues and expenses and reflect the ongoing financial results of the insurer. For example, in accordance with SAP, commissions and other costs incurred in connection with acquiring new business are charged to operations in the year incurred, whereas in accordance with GAAP, certain of these expenses are deferred and amortized on a basis to match them against appropriate revenues.

In accordance with SAP, New York Life's financial statements are not consolidated and investments in subsidiaries are generally shown at net equity value. Accordingly, the assets, liabilities and results of operations of New York Life's subsidiaries are not consolidated with the assets, liabilities and results of operations, respectively, of New York Life. However, New York Life's financial statements reflect, in New York Life's assets, the net equity value of New York Life's subsidiaries and, in New York Life's surplus, the current year change in net equity value of subsidiaries, less contributions received from or returns of capital paid to New York Life, as an unrealized gain or loss on investments. Dividends declared by subsidiaries to New York Life are included in New York Life's net investment income.

Discussion of Certain Differences between SAP and GAAP

The financial information of New York Life is presented in accordance with SAP. Statutory accounting is used by state insurance regulators to monitor the operations of insurance companies. Financial statements prepared in accordance with SAP as determined under New York Insurance Law vary from those prepared in accordance with GAAP in certain material respects, primarily as follows:

### Investments

- debt securities must meet a principles-based bond definition ("PBBD") in order to be reported as bonds in accordance with SAP, whereas a PBBD does not exist for GAAP;
- investments in bonds are generally carried at amortized cost or values as prescribed by the NYSDFS. Investments in bonds that do not meet the PBBD are generally reported at the lower of cost or market. in accordance with GAAP, investments in bonds that are classified as available for sale or trading are carried at fair value, with changes in fair value of bonds classified as available for sale reflected in equity, and changes in fair value of bonds classified as trading reflected in earnings;
- credit loss-related bond impairments that are deemed to be other than temporary are recorded as a direct
  write-down to the security without the ability to reverse those losses in the future if expected cash flows
  increase. In accordance with GAAP, estimated credit losses on bonds classified as available for sale are
  recorded through an allowance for credit losses subject to future reversals if expected cash flows
  increase;
- investments in subsidiaries, controlled and other affiliated entities as defined in Statements of Statutory Accounting Principles No. 97, "Investments in Subsidiary, Controlled and Affiliated Entities" ("SCAs"), including partnerships, limited liability companies and joint ventures, are accounted for under the equity method. Under the equity method, domestic insurance subsidiaries are recorded at their underlying audited statutory surplus. Nonpublic non-insurance subsidiaries and other controlled entities are recorded at their underlying audited GAAP equity. Changes in the value of such investments are recorded

as unrealized gains or losses. The earnings of such investments are recorded in net investment income only when dividends are declared. In accordance with GAAP, these investments are consolidated;

- investments in noncontrolled partnerships and limited liability companies are accounted for under the equity method in accordance with both SAP and GAAP. Under the statutory equity method, undistributed income and capital gains and losses for these investments are reported in surplus as unrealized gains or losses, whereas in accordance with GAAP, in many cases, for investment companies, unrealized gains and losses are included in net investment income;
- for investments in mortgage loans, specific valuation allowances are established for the excess carrying value of a mortgage loan over the estimated fair value of the collateral as an unrealized loss in surplus when it is probable that based on current information and events, New York Life will be unable to collect amounts due under the contractual terms of the loan agreement. In accordance with GAAP, a valuation allowance is established for expected credit losses. The valuation allowance in accordance with GAAP is based on historical experience, current economic conditions and reasonable and supportable forecasts;
- realized gains and losses resulting from changes in interest rates are deferred in the IMR and amortized into investment income over the remaining life of the investment sold, whereas in accordance with GAAP, the gains and losses are recognized in income at the time of sale;
- certain derivative instruments are carried at amortized cost, whereas in accordance with GAAP, all derivative instruments are carried at fair value;

### **Insurance Contracts**

- contracts that have any mortality or morbidity risk, regardless of significance, and contracts with life contingent annuity purchase rate guarantees are classified as insurance contracts, whereas in accordance with GAAP, only contracts that have significant mortality or morbidity risk are classified as insurance contracts, otherwise they are accounted for in a manner consistent with the accounting for interest bearing or other financial instruments;
- payments received for universal and variable life insurance products, certain variable and fixed deferred annuities and group annuity contracts are reported as premium income and corresponding change in reserves, whereas GAAP would treat these payments as deposits to policyholders' account balances;
- the costs related to acquiring insurance contracts (principally commissions), policy issue expenses and sales inducements are charged to income in the period incurred, whereas in accordance with GAAP, these costs are deferred when related directly to successful sales and amortized over the periods benefited;
- life insurance and annuity reserves are based on different statutory methods and assumptions than they are in accordance with GAAP;
- reinsurance agreements are accounted for as reinsurance on a SAP and GAAP basis if certain risk transfer provisions have been met. SAP requires the reinsurer to assume insurance risk, regardless of the significance of the loss potential, whereas GAAP requires that there is a reasonable possibility that the reinsurer may realize significant loss from assuming insurance risk; assets and liabilities from reinsurance transactions are reported net of reinsurance, whereas in accordance with GAAP, assets and liabilities from reinsurance transactions are reported gross of reinsurance;

### Taxes

deferred income taxes exclude state income taxes and are admitted to the extent they can be realized
within three years subject to a 15% limitation of capital and surplus with changes in the net deferred tax
reflected as a component of surplus, whereas in accordance with GAAP, deferred income taxes include

federal and state income taxes and changes in deferred taxes are reflected in either earnings or other comprehensive income;

• a tax loss contingency is required to be established if it is more likely than not that a tax position will not be sustained upon examination by taxing authorities. If a loss contingency is greater than 50% of the tax benefit associated with a tax position, the loss contingency is increased to 100%, whereas in accordance with GAAP the amount of the benefit for any uncertain tax position is the largest amount that is greater than 50% likely of being realized upon settlement;

### Surplus

- an AVR based on a formula prescribed by the NAIC is established as a liability to offset potential noninterest related investment losses. Changes in the AVR are recorded directly to surplus, whereas in accordance with GAAP, no AVR is recognized;
- certain assets, such as investments in SCA entities that do not have audited financial statements, deferred taxes as noted above, intangible assets, overfunded pension plan assets, furniture and equipment, and unsecured receivables are considered nonadmitted and excluded from assets, whereas they are included in assets in accordance with GAAP subject to a valuation allowance, as appropriate;
- surplus notes are included as a component of surplus, whereas in accordance with GAAP, they are presented as a liability; and

### Other

• goodwill held by an insurance company is admitted subject to a 10% limitation on surplus and amortized over the useful life of the goodwill, not to exceed 10 years, and goodwill held by non-insurance subsidiaries is assessed in accordance with GAAP, subject to certain limitations for holding companies and foreign insurance subsidiaries, whereas in accordance with the GAAP private company accounting alternative, goodwill is amortized over the useful life of the goodwill, not to exceed 10 years, and is tested for impairment, but it is not subject to the 10% limitation on equity.

The effects on the financial statements of the above variances between SAP as determined under New York Insurance Law and in accordance with GAAP are material to New York Life.

Adjustments for Impaired Investments

The cost basis of bonds and equity securities is adjusted for impairments in value deemed to be other-thantemporary, with the associated realized loss reported in net income. For a discussion of how New York Life determines whether an impairment is appropriate, see "Management's Discussion and Analysis of Financial Condition and Results of Operations—New York Life's Investment Portfolio."

Statutory Investment Reserves

SAP requires a life insurance company to maintain both an AVR and an IMR to absorb both realized and unrealized gains and losses on a portion of the life insurance company's investments. The AVR is an investment reserve established to provide for default risk on fixed income assets and market value fluctuation on equity-type investments. The amount of the AVR is determined by formula, which considers the type of investment, the credit rating (where applicable) and current year changes in realized and unrealized capital gains and losses (other than those resulting from changes in interest rates). Changes in the AVR are accounted for as direct increases or decreases in surplus.

The IMR applies to interest-sensitive investments including bonds, preferred stocks, mortgage-backed securities, asset-backed securities, mortgage loans and certain derivatives. The IMR is designed to capture the after-tax capital gains or losses which are realized upon the sale of such investments and which result from changes in the

overall level of interest rates. The captured after-tax net realized gains or losses are then amortized into income. In accordance with the NAIC's interim statutory accounting guidance, insurers are allowed to admit negative IMR (i.e., when deferred cumulative realized losses exceed cumulative realized gains) as special surplus for admitted disallowed IMR up to 10% of its capital and surplus as required to be shown on the balance sheet of the statutory financial statements most recently filed by such insurer with its domiciliary state insurance regulator, adjusted to exclude any net positive goodwill, electronic database processing equipment and operating system software, net deferred tax assets and admitted net negative IMR. Only insurers with a risk-based capital greater than 300% authorized control level can admit negative IMR. Most of New York Life's admitted disallowed IMR relates to realized losses on derivatives. New York Life uses derivatives to hedge reinvestment risk by locking in a yield. The amortization of the IMR derivative losses is offset by higher investment income earned on new bonds.

### **Dividends to Policyholders**

New York Life annually determines the amount of dividends payable to eligible policyholders. These dividends have the effect of reducing the cost of insurance to policyholders and should be distinguished from the dividends paid on shares of capital stock by other types of business corporations or by stock life insurance companies. Policies on which such dividends may be payable are referred to as participating policies; policies on which such dividends are not payable are referred to as non-participating policies.

Annually, the Board of Directors approves the divisible surplus of New York Life to be paid out to eligible policyholders in accordance with an actuarially determined dividend scale. New York Life has discretion, subject to statutory requirements as to the source of dividends, to vary the amount of dividends payable to policyholders, even many years after the issuance of a particular policy. In determining the policyholder dividends payable in any year, the Board of Directors considers, among other things, the amounts necessary to meet New York Life's future policy obligations, maintain reserves and operate the business. To the extent authorized by the Board of Directors, New York Life has the right to continue to declare policyholder dividends and to make dividend payments on its participating policies.

### **Policy Reserves**

Life insurance companies price their insurance products based upon assumptions regarding certain future events, including investment income, expenses incurred and use of mortality and morbidity tables. SAP prescribes methods for providing for future benefits to be paid on a conservative basis, primarily by charging current operations with amounts necessary to establish appropriate reserves for anticipated future claims. Thus, under applicable state law, New York Life must maintain reserves in amounts which are actuarially calculated to be sufficient to meet its various policy and contract obligations as they become due. Such reserves appear as liabilities on New York Life's financial statements.

New York Life is required under the New York Insurance Law to conduct annually an analysis of the sufficiency of all life insurance and annuity statutory reserves. New York Life conducts its annual analysis as of December 31, see "Regulation and Supervision—Insurance Regulation—Policy and Contract Reserve Sufficiency Analysis."

### Reinsurance

New York Life uses a variety of reinsurance agreements with insurers to control its loss exposure. Generally, these agreements are structured either on an automatic basis, where all risks meeting prescribed criteria are automatically covered, or on a facultative basis, where the reinsurer must accept the specific reinsurance risk before the reinsurer becomes liable on that risk. The amount of each risk retained by New York Life on a facultative basis depends on its evaluation of the specific risk, its maximum retention limits and the amount of reinsurance available.

Divisible surplus is the portion of New York Life's total surplus that is available, following each year's operations, for distribution in the form of dividends.

Under the terms of the reinsurance agreements, the reinsurers will be liable to reimburse New York Life for the ceded amount in the event a claim on a reinsured policy is paid. New York Life remains primarily liable for all claims payable on reinsured policies, even if the reinsurer fails to meet its obligations under the reinsurance agreement. New York Life routinely collects amounts due from its reinsurers on a timely basis. For more information, see "Description of the Business of the Company—Reinsurance."

New York Life is a party to a reinsurance agreement (the "Closed Block Reinsurance") with John Hancock Life Insurance Company (U.S.A.) and one of its affiliates ("John Hancock") in which New York Life assumes on a coinsurance basis 100% of John Hancock's obligations and liabilities under the policies included in the closed block of participating whole life policies established in connection with the demutualization of John Hancock Mutual Life Insurance Company (the "Closed Block"). New York Life retrocedes 40% of those obligations and liabilities to John Hancock on a funds-withheld arrangement. The assets received from this transaction are held in a reinsurance trust as security for New York Life's obligations to John Hancock and are contractually restricted. The majority of such assets are allocated to the Closed Block and are held for the exclusive benefit of the policies included in the Closed Block.

The insurance-related revenue from the Closed Block policies, including net investment income from the assets allocated to the Closed Block, after satisfying certain related expenses and taxes, inure solely to the benefit of those reinsured policyholders and will not be available to New York Life's policyholders. Dividends for the Closed Block are approved by John Hancock.

Effective December 31, 2023, New York Life entered into a strategic indemnity reinsurance agreement on a coinsurance with funds withheld basis (the "Term Reinsurance Agreement") with Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft ("Munich Re"). Under the Term Reinsurance Agreement, New York Life ceded on a quota share basis 85% of all the risks under certain term life policies and respective riders issued by New York Life between January 1, 2000 and December 31, 2019. New York Life pays Munich Re an annual risk and profit charge which will decrease over time. New York Life receives from Munich Re a quarterly experience refund if the experience refund formula is positive.

### **Separate Accounts**

Under state insurance laws, insurers are permitted to establish separate investment accounts in which assets backing certain policies, including certain group annuity contracts, are held. The investments in each separate account (which may be pooled or customer-specific) are maintained separately from those in other separate accounts and the general account. Generally, the investment results of the separate account assets pass through to separate account policyholders and contract holders, so that an insurer derives management and other fees from, but bears no investment risk on, these assets. In separate accounts for products with minimum interest rate guarantees, the risk that the investment results of the separate account assets will not meet the minimum rate guaranteed on these products is borne by the insurer.

# STATUTORY CAPITALIZATION OF NEW YORK LIFE

New York Life is a mutual insurance company incorporated under the laws of the State of New York, United States. New York Life was incorporated on May 21, 1841 under the name Nautilus Insurance Company, was licensed to transact business in the State of New York on April 17, 1845 and changed its name to New York Life Insurance Company on April 5, 1849. The U.S. federal employer identification number of New York Life is 13-5582869. The registered office of New York Life is 51 Madison Avenue, New York, New York 10010. The telephone number of New York Life is +1 (800) 692-3086.

As a mutual company, New York Life has no capital stock and no shareholders. New York Life's participating policyholders generally have certain rights to receive policy dividends, and they and certain other policyholders may have rights to receive distributions in a proceeding for its rehabilitation, liquidation or dissolution. Policyholders also have certain rights to vote in the election of directors as provided by New York law.

New York Life's balance sheet includes its surplus and an AVR. The amount by which the admitted assets of New York Life exceed its liabilities is referred to as surplus. The AVR stabilizes surplus from fluctuations in the value of the investment portfolio (see "Certain Financial and Accounting Matters—Accounting Policies and Principles—Statutory Investment Reserves").

The following table sets forth the capitalization of New York Life at June 30, 2025. The AVR is included in the following table even though such reserve is shown as a liability on New York Life's balance sheet. This treatment is consistent with the general view of the insurance industry. In addition, this reserve is included as part of total adjusted capital for RBC purposes.

	 une 30, 2025 millions)
Total Short-Term Debt (less than 1 year)	\$ 418
AVR	\$ 4,748
Surplus:	
Surplus notes	4,234
Special surplus for admitted disallowed IMR <sup>1</sup>	793
Unassigned funds	20,655
Surplus and AVR	\$ 30,430

<sup>1</sup> See "Certain Financial and Accounting Matters—Accounting Policies and Principles—Statutory Investment Reserves."

# SELECTED HISTORICAL STATUTORY FINANCIAL INFORMATION OF NEW YORK LIFE

The table presented below sets forth selected financial information for New York Life. Prospective investors should read it in conjunction with "Certain Financial and Accounting Matters" and New York Life's Statutory Financial Statements included in the Offering Memorandum. The selected financial information for New York Life's Statement of Financial Position and Statement of Operations at or for the years ended December 31, 2024, 2023 and 2022 has been derived from the annual audited statutory financial statements. The selected financial information for New York Life at or for the six months ended June 30, 2025 and 2024 has been derived from the quarterly unaudited statutory financial statements.

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements. Actual results may differ from estimates. Historical results are not necessarily indicative of results for any future period.

	At or for the Six Months Ended June 30,			At or for the Year Ended December 31,				
_	2025	2024		2024		2023	2022	
			(in	millions)				
Statement of Operations Data:								
Total income	\$ 14,376	\$ 13,766	\$	27,193	\$	23,838	\$ 25,880	
Dividends to policyholders <sup>1</sup>	1,405	1,259		2,651		2,389	2,131	
Net (loss)/gain from operations	(106)	742		846		70	170	
Net (loss)/income	(286)	768		470		28	15	
Statement of Financial Position Data:								
Total assets	\$ 251,980	\$ 240,119	\$	244,901	\$	231,902	\$ 222,781	
Total liabilities	\$ 226,298	\$ 214,481	\$	218,474	\$	206,608	\$ 198,894	
Surplus:								
Surplus notes	4,234	4,233		4,233		4,232	4,232	
Special surplus for admitted disallowed IMR <sup>2</sup>	793	778		804		435	_	
Unassigned funds	20,655	20,627		21,390		20,627	19,655	
Surplus	25,682	25,638		26,427		25,294	23,887	
Asset valuation reserve <sup>3</sup>	4,748	4,506		4,588		4,513	4,235	
Surplus and asset valuation reserve	\$ 30,430	\$ 30,144	\$	31,015	\$	29,807	\$ 28,122	
Other Data:								
Equity investment in subsidiaries <sup>4</sup>	\$ 14,906	\$ 14,299	\$	14,738	\$	14,373	\$ 13,617	

<sup>1</sup> Dividends to policyholders (excluding dividends on assumed reinsurance) are discretionary and subject to the approval of the Board of Directors and dividends for the Closed Block are approved by the ceding company.

<sup>2</sup> See "Certain Financial and Accounting Matters—Accounting Policies and Principles—Statutory Investment Reserves."

Included in Total liabilities above but are treated as part of adjusted capital in the calculation of RBC.

<sup>4</sup> Included in Total assets above.

# NEW YORK LIFE INSURANCE COMPANY CONDENSED STATUTORY FINANCIAL STATEMENTS

For the quarterly period ended June 30, 2025

# **NEW YORK LIFE INSURANCE COMPANY**

# CONDENSED STATUTORY STATEMENTS OF FINANCIAL POSITION (UNAUDITED)

	June 30, 2025		Dec	cember 31, 2024
		s)		
Assets Bonds	\$	150,654	\$	146,462
Common and preferred stocks	Ψ	14,059	Ψ	14,092
Mortgage loans		26,093		23,786
Policy loans		14,411		13,898
Other invested assets		14,904		14,231
Cash, cash equivalents and short-term investments		3,383		4,231
Derivatives		1,582		1,489
Real estate		2,377		2,343
Total cash and invested assets		227,463		220,532
Deferred and uncollected premiums		1,959		1,689
Investment income due and accrued		2,278		2,380
Admitted disallowed interest maintenance reserve		793		804
Other assets		8,220		7,862
Separate accounts assets		11,267		11,634
Total assets	\$	251,980	\$	244,901
Liabilities and surplus				
Liabilities:			_	
Policy reserves	\$	145,047	\$	142,176
Deposit funds		50,396		44,519
Dividends payable to policyholders		2,667		2,608
Policy claims		925		802
Borrowed money		418		450
Amounts payable under security lending agreements		572		688
Derivatives		790		1,271
Funds held under coinsurance		3,359		3,476
Other liabilities		6,109		6,262
Asset valuation reserve		4,748		4,588
Separate accounts liabilities		11,267		11,634
Total liabilities		226,298		218,474
Surplus:				
Surplus notes		4,234		4,233
Special surplus for admitted disallowed interest maintenance reserve		793		804
Unassigned surplus		20,655		21,390
Total surplus		25,682		26,427
Total liabilities and surplus	\$	251,980	\$	244,901

# NEW YORK LIFE INSURANCE COMPANY CONDENSED STATUTORY STATEMENTS OF OPERATIONS (UNAUDITED)

# Six Months Ended June 30,

	04110 00,				
		<u>2025</u> <u>2024</u>			
		(in millions)			
Income					
Premiums	\$	9,835	\$	8,699	
Net investment income		4,425		4,931	
Other income		116		136	
Total income		14,376		13,766	
Benefits and expenses					
Benefit payments:					
Death benefits		2,274		2,264	
Annuity benefits		849		814	
Health and disability insurance benefits		170		170	
Surrender benefits		1,376		1,284	
Payments on matured contracts		3,586		2,443	
Other benefit payments		871		686	
Total benefit payments		9,126		7,661	
Additions to reserves		2,938		2,965	
Net transfers from separate accounts		(702)		(717)	
Adjustment in funds withheld		69		71	
Operating expenses		1,696		1,818	
Total benefits and expenses		13,127		11,798	
Gain from operations before dividends to policyholders and		4.040		4.000	
federal and foreign income taxes		1,249		1,968	
Dividends to policyholders	-	1,405		1,259	
(Loss)/gain from operations before federal and foreign income taxes		(156)		709	
Federal and foreign income taxes		(50)		(33)	
Net (loss)/gain from operations		(106)		742	
Net realized capital (losses)/gains, after tax and transfers to					
interest maintenance reserve		(180)		<u>26</u>	
Net (loss) income	\$	(286)	\$	768	

# NEW YORK LIFE INSURANCE COMPANY CONDENSED STATUTORY STATEMENTS OF CHANGES IN SURPLUS (UNAUDITED)

	June 30, 2025	Dec	ember 31, 2024	
	(in millions)			
Surplus, beginning of year	\$ 26,427	\$	25,294	
Net income	(286)		470	
Change in liability for pension and post-retirement plans	(32)		162	
Change in asset valuation reserve	(161)		(75)	
Change in nonadmitted assets	(407)		577	
Change in net deferred income tax	124		334	
Change in surplus as a result of reinsurance	(32)		(14)	
Change in net unrealized capital gains on investments	257		97	
Goodwill amortization	(210)		(418)	
Other adjustments, net	 2		<u> </u>	
Surplus, end of period	\$ 25,682	\$	26,427	

# NEW YORK LIFE INSURANCE COMPANY CONDENSED STATUTORY STATEMENTS OF CASH FLOWS (UNAUDITED)

# Six Months Ended June 30,

		2025		2024		
	(in millions)					
Cash flows from operating activities:						
Premiums received	\$	9,545	\$	8,414		
Net investment income received		4,395		4,020		
Other		120		183		
Total received		14,060		12,617		
Benefits and other payments		8,202		6,818		
Net transfers from separate accounts		(697)		(675)		
Operating expenses		1,878		1,920		
Dividends to policyholders		1,346		1,193		
Federal income taxes paid		100		404		
Total paid		10,829		9,660		
Net cash from operating activities		3,231		2,957		
Cash flows from investing activities:						
Proceeds from investments sold		11,175		6,755		
Proceeds from investments matured or repaid		8,175		6,339		
Cost of investments acquired		(25,708)		(18,651)		
Net change in policy loans and premium notes		(513)		(509)		
Net cash used in investing activities		(6,871)		(6,066)		
Cash flows from financing and miscellaneous activities:						
Borrowed funds		(32)		(4)		
Net inflows from deposit contracts		3,466		4,184		
Other miscellaneous uses		(642)		(725)		
Net cash from financing and miscellaneous activities		2,792		3,455		
Net (decrease)/increase in cash, cash equivalents and short-term investments		(848)		346		
Cash, cash equivalents and short-term investments, beginning of year		4,231		3,595		
Cash, cash equivalents and short-term investments, end of period	\$	3,383	\$	3,941		

### **NOTE 1 - NATURE OF OPERATIONS**

### BASIS OF PRESENTATION

The accompanying financial statements of New York Life Insurance Company ("the Company") have been prepared using accounting practices prescribed by the New York State Department of Financial Services ("NYSDFS" or "the Department").

The Department recognizes only statutory accounting practices prescribed or permitted by the State of New York for determining and reporting the financial position and results of operations of an insurance company and for determining its solvency under New York Insurance Law. The National Association of Insurance Commissioners' ("NAIC") Accounting Practices and Procedures Manual ("NAIC SAP") has been adopted as a component of prescribed practices by the State of New York. Prescribed statutory accounting practices include state laws and regulations. Permitted statutory accounting practices encompass accounting practices that are not prescribed; such practices differ from state to state, may differ from company to company within a state, and may change in the future. The Company has no permitted practices.

A reconciliation of the Company's net income and capital and surplus at June 30, 2025 and December 31, 2024 between practices prescribed or permitted by the State of New York and NAIC SAP is shown below (in millions):

	SSAP#	F/S Page	F/S Line #		2025		2025		2024
Net Income									
Net income, New York State basis (1) (Page 4, Line 35, Columns 1 & 3) State prescribed practices that increase/(decrease)	XXX	XXX	XXX	\$	(286)	\$	470		
(2) NAIC SAP:									
NYSDFS Regulation No. 213 principle-based reserving and No. 151 minimum life and annuity reserves*	51R	3	1		(21)		(65)		
NYSDFS Circular Letter No. 11 (2010) impact on deferred premiums**	61	2, 4, 5	15.2, 1, 1		2		14		
NYSDFS Seventh Amendment to Regulation No. 172 impact on admitted unearned reinsurance premium***	61	2, 4, 5	15.2, 1, 1		(1)		(3)		
(3) State permitted practices that increase/(decrease) NAIC SAP:					_				
(4) Net income, NAIC SAP (1-2-3=4)	XXX	XXX	XXX	\$	(266)	\$	524		
Capital and Surplus									
Statutory capital and surplus, New York State basis (5) (Page 3, Line 38, Columns 1 & 2)	XXX	XXX	XXX	\$	25,682	\$	26,427		
State prescribed practices that increase/(decrease)  (6) NAIC SAP:									
NYSDFS Regulation No. 213 principle-based reserving and No. 151 minimum life and annuity reserves*	51R	3	1		(241)		(220)		
NYSDFS Circular Letter No. 11 (2010) impact on deferred premiums**	61	2, 4, 5	15.2, 1, 1		(108)		(110)		
NYSDFS Seventh Amendment to Regulation No. 172 impact on admitted unearned reinsurance premium***	61	2, 4, 5	15.2, 1, 1		57		58		
State permitted practices that increase/(decrease)  NAIC SAP:					_		_		
(8) Capital and surplus, NAIC SAP (5-6-7=8)	XXX	XXX	XXX	\$	25,974	\$	26,699		

<sup>\*</sup> NYSDFS Regulation 213 subjects principle-based valuations as prescribed by the valuation manual to minimum New York State requirements; NYSDFS Regulation 151 prescribes rules and guidelines for performing valuations of annuity, single premium life insurance guaranteed interest contract and other deposit reserves

<sup>\*\*</sup> NYSDFS Circular Letter No. 11 (2010) clarified the accounting for deferred premium assets when reinsurance is involved.

<sup>\*\*\*</sup> NYSDFS Regulation 172 was amended to allow for the admission of an unearned reinsurance premium asset.

### Note 2 - Fair Value Measurements

- A. The Company's financial assets and liabilities carried at fair value have been classified, for disclosure purposes, based on a hierarchy defined by SSAP No. 100, "Fair Value Measurements". Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. This guidance establishes a framework for measuring fair value that includes a hierarchy used to classify the inputs used in measuring fair value. The hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels. The level in the fair value hierarchy within which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement.
- (1) The levels of the fair value hierarchy are based on the inputs to the valuation as follows:
- **Level 1** Fair value is based on unadjusted quoted prices for identical assets or liabilities in an active market. Active markets are defined as a market in which many transactions occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
- Level 2 Observable inputs other than level 1 prices, such as quoted prices in active markets for similar assets or liabilities; quoted prices in markets that are not active for identical or similar assets or liabilities, or other model driven inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Valuations are generally obtained from third-party pricing services for identical or comparable assets or liabilities or through the use of valuation methodologies using observable market inputs.
- Level 3 Instruments whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management's own assumptions in pricing the asset or liability. Pricing may also be based upon broker quotes that do not represent an offer to transact. Prices are determined using valuation methodologies such as option pricing models, discounted cash flow models and other similar techniques. Non-binding broker quotes, which are utilized when pricing service information is not available, are reviewed for reasonableness based on the Company's understanding of the market, and are generally considered Level 3. To the extent the internally developed valuations use significant unobservable inputs, they are classified as Level 3.

The following table represents the balances of assets and liabilities measured at fair value or net asset value ("NAV") as of June 30, 2025 (in millions):

			Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Net Asset Value (NAV)	Total
a.	Ass	eets at fair value					
		Perpetual preferred stocks	\$	\$ 43	\$ 111	_	\$ 154
	1.	Preferred stocks		43	111	_	154
	2.	Bonds					
		Issuer Credit Obligations	86	6	4	_	96
		Asset-Backed Securities		19		_	19
	•	Total bonds	86	25	4		115
	3.	Common stocks	266	_	234	_	500
	4.	Derivative assets Interest rate swaps		126			126
		Foreign currency swaps	_	52	_		52
		Inflation swaps	_	3	_	_	3
		Interest rate options	_	19	_	_	19
		Foreign currency forwards	_	_	_	_	_
		Futures	_	_	_	_	_
		Total derivative assets		200	_	_	200
	5.	Separate accounts assets	514	2,758	5	1,163	4,440
	6.	Other invested assets		56	43	_	99
	Tot	al assets at fair value	\$ 866	\$ 3,082	\$ 397	\$ 1,163	\$ 5,508
b.	Lial	pilities at fair value					
	1.	Derivative liabilities					
		Interest rate swaps	\$ —	\$ 235	\$ —	\$ —	\$ 235
		Foreign currency swaps	_	15	_	_	15
		Inflation swaps	_	21	_	_	21
		Interest rate options	_		_	_	_
		Foreign currency forwards Futures	_	30	_	_	30
		Total derivative liabilities	_	301	_	_	301
	2.	Separate accounts liabilities - derivatives <sup>1</sup>	1		_	_	1
	Tot	al liabilities at fair value	\$ 1	\$ 301	\$ —	\$ —	\$ 302
		navete appoints contract helder liebilities are not in	aluded in the table				n the Commonvile

<sup>&</sup>lt;sup>1</sup> Separate accounts contract holder liabilities are not included in the table as they are reported at contract value and not fair value in the Company's Annual Statement.

(2) The table below presents a roll forward of level 3 assets and liabilities for the three months ended June 30, 2025 (in millions):

	Balance at 04/01/2025		Transfers into Level 3		Transfers out of Level 3		Total gains or (losses) included in Net		Total gains or (losses) included in Surplus		Purchases		Issuances		 Sales		Settlement s		Balance at 06/30/2025	
Assets:																				
Preferred stocks Bonds		110	\$	_	\$	_	\$	_	\$	_	\$	1	\$	_	\$ _	\$	_	\$	111	
Issuer Credit Obligations		4		_		_		_		_		1		_	_		_		5	
Asset- Backed Securities		_						_				_					_			
Total bonds		4		_		_		_		_		1		_	_		_		5	
Common stocks		238		_		_		_		_		82		_	(86)		_		234	
Derivatives				_		_		_		_		_		_	_		_			
Separate accounts assets <sup>1</sup> Other invested		1		2		_		1		(2)		3		_	(1)		_		4	
assets		32		37		(30)		(4)				8		_	_		_		43	
Total Assets:	\$	385	\$	39	\$	(30)	\$	(3)	\$	(2)	\$	95	\$	_	\$ (87)	\$	_	\$	397	
Liabilities:																				
Derivatives	\$	_	\$	_	\$		\$	_	\$	_	\$	_	\$	_	\$ 	\$	_	\$		
Total Liabilities	\$	_	\$		\$		\$		\$		\$		\$		\$ 	\$		\$		

<sup>&</sup>lt;sup>1</sup> The total gains or (losses) included in surplus for separate accounts assets are offset by an equal amount for separate accounts liabilities, which results in a net zero impact on surplus for the Company.

### Transfers between levels

Transfers between levels may occur due to changes in valuation sources, or changes in the availability of market observable inputs, which generally are caused by changes in market conditions such as liquidity, trading volume or bid-ask spreads, or as a result of a security measured at amortized cost at the beginning of the period, but measured at estimated fair value at the end of the period, or vice versa due to a ratings downgrade or upgrade.

### Transfers into and out of Level 3

The Company's basis for transferring assets and liabilities into and out of Level 3 is based on changes in the observability of data, a change in the security's measurement or changes in redemption restrictions of certain separate account investments.

Transfers into Level 3 totaled \$39 million for the three months ended June 30, 2025, which relate to \$37 million of other invested assets residual tranches of securitizations that were measured at amortized cost at the beginning of the period and measured at fair value at the end of the period and separate account assets of \$2 million related to a change in price source of corporate bonds. Transfers out of Level 3 totaled \$30 million for the three months ended June 30, 2025 which relate to \$30 million other invested assets residual tranches of securitizations that were measured at fair value at the beginning of the period and measured at amortized cost at the end of the period.

### (3) Determination of fair value

The Company has an established and well-documented process for determining fair value. Security pricing is applied using a hierarchy approach whereby publicly available prices are first sought from nationally recognized third-party pricing services. For most private placement securities, the Company applies a matrix-based pricing methodology, which uses spreads derived from third-party benchmark bond indices. For private placement securities that cannot be priced through these processes, the Company uses internal models and calculations. All other securities are submitted to independent brokers for prices. The Company performs various analyses to ascertain that the prices represent fair value. Examples of procedures performed include, but are not limited to, back testing recent trades, monitoring trading volumes, and performing variance analysis of monthly price changes using different thresholds based on asset type. The Company also performs an annual review of all third-party pricing services. During this review, the Company obtains an understanding of the process and sources used by the pricing service to ensure that they maximize the use of observable inputs, the pricing service's frequency of updating prices, and the controls that the pricing service uses to ensure that their prices reflect market assumptions. The Company also selects a sample of securities and obtains a more detailed understanding from each pricing service regarding how they derived the price assigned to each security. Where inputs or prices do not reflect market participant assumptions, the Company will challenge these prices and apply different methodologies that will enhance the use of observable inputs and data. The Company may use non-binding broker quotes or internal valuations to support the fair value of securities that go through this formal price challenge process.

At June 30, 2025 the Company did not have any price challenges on general account and separate account securities for what it received from third party pricing services.

In addition, the Company has a pricing committee that provides oversight over the Company's prices and fair value process for securities. The committee meets quarterly and is responsible for the review and approval of the Company's valuation procedures. The committee is also responsible for the review of pricing exception reports as well as the review of significant inputs used in the valuation of assets that are valued internally.

For Level 1 investments, valuations are generally based on observable inputs that reflect quoted prices for identical assets in active markets.

The fair value for Level 2 and Level 3 valuations are generally based on a combination of the market and income approach. The market approach generally utilizes market transaction data for the same or similar instruments, while the income approach involves determining fair values from discounted cash flow methodologies.

The following represents a summary of significant valuation techniques for assets and liabilities used to determine fair value, as well as the general classification of such instruments pursuant to the valuation hierarchy.

### **Level 1 measurements**

### SVO identified bond ETF

For U.S. SAP, certain SVO approved ETF and mutual funds. Valuation of these securities is based on unadjusted quoted prices in active markets that are readily and regularly available. All other ETFs and mutual funds are classified and accounted for as common stock.

### Common stocks

These securities are comprised of exchange traded U.S. and foreign common stock and mutual funds. The fair value of these securities is primarily based on unadjusted quoted prices in active markets that are readily and regularly available.

Derivatives (including separate accounts liabilities – derivatives)

These derivatives are comprised of exchange traded future contracts. The fair value of these securities is primarily based on unadjusted quoted prices in active markets that are readily and regularly available.

### Separate accounts assets

These assets are comprised of cash and common stocks. Common stocks are generally traded on an exchange.

### Level 2 measurements

#### Preferred stocks

The fair value of preferred stock is obtained from third-party pricing services. Vendors generally use an income-based valuation approach by using a discounted cash flow model or it may use a market approach to arrive at the security's fair value or a combination of the two.

#### Bonds

The fair value of bonds is obtained from third-party pricing services, matrix-based pricing, internal models or broker quotes. Third-party pricing services generally use an income-based valuation approach by using a discounted cash-flow model or it may also use a market approach by looking at recent trades of a specific security to determine fair value on public securities or a combination of the two. Typical inputs used by these pricing services include, but are not limited to: benchmark yields, reported trades, issuer spreads, bids, offers, benchmark securities, estimated cash flows and prepayment speeds, which the Company has determined are observable inputs.

Private placement securities are primarily priced using a market approach such as a matrix-based pricing methodology, which uses spreads derived from third-party benchmark bond indices. Specifically, the Barclays Investment Grade Corporate Index is used for investment-grade securities and the Citi High Yield Cash Index is used for below investment-grade securities. These indices are two widely recognized, reliable and well regarded benchmarks by participants in the financial services industry, which represent the broader U.S. public bond markets. The spreads derived from each matrix are adjusted for liquidity. The liquidity premium is standardized and based on market transactions.

Certain private placement securities that cannot be priced using the matrix pricing described above, are priced by an internally developed discounted cash flow model or are priced based on internal calculations. The model uses observable inputs with a discount rate based off spreads of comparable public bond issues, adjusted for liquidity, rating and maturity. The Company assigns a credit rating for private placement securities based upon internal analysis. The liquidity premium is usually based on market transactions. These securities are classified as Level 2.

For some of the private placement securities priced through the model, the liquidity adjustments may not be based on market data, but rather, calculated internally. If the impact of the liquidity adjustment, which usually requires the most judgment, is not significant to the overall value of the security, the security is still classified as Level 2. If it is deemed to be significant, the security is classified as Level 3.

### Derivatives

The fair value of derivative instruments is generally derived using valuation models that use an income approach, except for derivatives, which are either exchange-traded, or the fair value is priced using broker quotations. The selection of a particular model depends upon the contractual terms of, and specific risks inherent in the instrument, as well as the availability of pricing information in the market. The Company generally uses similar models to value similar instruments. Valuation model inputs include contractual terms, yield curves, foreign exchange rates, equity prices, credit curves, measures of volatility, and other factors. OTC derivatives that trade in liquid markets, where model inputs are observable for substantially the full term, are classified as Level 2.

### Other invested assets

Other invested assets include residual tranches of securitizations where the fair value is obtained from third-party pricing services. Vendors generally use an income valuation approach which is based on a discounted cash flow calculation to arrive at the fair value.

### Separate accounts assets

These are assets primarily related to investments in U.S. government and treasury securities, corporate bonds and mortgage-backed securities. These separate accounts assets are valued and assigned within the fair value hierarchy, consistent with the methodologies described herein for similar financial instruments held within the general account of the Company. This also relates to investments in limited partnerships and hedge funds that use NAV where the investment can be redeemed at NAV at the measurement date or in the near-term (generally 90 days).

### Level 3 measurements

#### Bonds

The valuation techniques for most Level 3 bonds are generally the same as those described in Level 2. However, if the investments are less liquid or are lightly traded, there is generally less observable market data, and therefore these investments will be classified as Level 3. Circumstances where observable market data are not available may include events such as market illiquidity and credit events related to the security. In addition, certain securities are priced based upon internal valuations using significant unobservable inputs. If a security could not be priced by a third-party vendor or through internal pricing models, broker quotes are received and reviewed by each investment analyst. These inputs may not be observable. Therefore, Level 3 classification is determined to be appropriate.

If the price received from third-party pricing services does not appear to reflect market activity, the Company may challenge the price. For securities which go through this formal price challenge process, a non-binding broker quote or internal valuation is used to support the fair value instead. The Company also uses non-binding broker quotes to fair value certain bonds, when the Company is unable to obtain prices from third-party vendors.

Private placement securities where adjustments for liquidity are considered significant to the overall price are classified as Level 3. Preferred and common stocks

These securities include equity investments with privately held entities, including a government organization, where the prices are derived from internal valuations.

### Derivatives

Derivatives that are valued based upon models with any significant unobservable market inputs or inputs from less actively traded markets, or where the fair value is solely derived using broker quotations, are classified as Level 3.

### Other Invested Assets

Other invested assets include preferred units of a limited partnership and residual tranches of securitizations. The fair value of the preferred units is derived internally based on market comparable and recent transactions by the limited partnership. This valuation technique used required inputs that were both unobservable and significant and therefore classified as Level 3. The fair value of the residual tranches of securitizations is derived using an income valuation approach, which is based on a discounted cash flow calculation that may or may not use observable inputs and is classified as Level 3.

### Separate accounts assets

Separate accounts assets reported as Level 3 relate to investments in common stocks and preferred stocks. These are instruments whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement

**B.** The following table presents the estimated fair value and carrying value of the Company's financial instruments at June 30, 2025. Since the SSAP 100 hierarchy only applies to items that are measured at fair value at the reporting date, the items in the tables above are subsets of the amounts reported in the following table (in millions):

	Fair Value	Ca	rrying Amount	Le	evel 1	Level	2	ı	_evel 3	N	et Asset Value (NAV)	Not Practica (Carryii Value	ıg	NAV Included in Level 2
Assets:														•
Issuer Credit Obligations	\$ 108,497	\$	117,795 \$	5	86 \$	1	04,616 \$	\$	3,795	\$	_	\$	_	\$ _
Asset Backed securities	31,371		32,859		_	:	29,168		2,203		_		_	_
Preferred stocks	231		228		_		43		188		_		_	_
Common stocks	499		499		266		_		234		_		_	_
Mortgage loans	24,923		26,093		_		_		24,923		_		_	_
Cash, cash equivalents and short-term investments	3,383		3,383		1,078		2,306		_		_		_	_
Derivatives	1,817		1,582		_		1,817		_		_		_	_
Other invested assets <sup>1</sup>	1,390		1,350		_		481		909		_		_	
Derivative Collateral	192		192		_		192		_				_	
Investment income due and accrued	2,278		2,278		_		2,278		_		_		_	_
Separate accounts assets	 11,109		11,215		603		9,264		79		1,163		_	_
Total assets	\$ 185,690	\$	197,474 \$	5	2,033 \$	1:	50,165 \$	\$	32,331	\$	1,163	\$	_	<u> </u>
Liabilities: Deposit fund contracts:														
Funding agreements	\$ 46,987	\$	47,379 \$	5	- \$		— \$	\$	46,987	\$	_	\$	_	\$
Annuities certain	10		10		_		_		10		_		_	_
Other deposit funds	_		1,227		_		_		_		_		_	_
Premiums paid in advance	115		_		_		115		_		_		_	_
Derivatives	845		790		_		845		_		_		_	_
Derivatives - collateral	508		508		_		508		_		_		_	_
Borrowed money	418		418		_		418		_		_		_	_
Payable to parent and affiliates	39		39		_		39		_		_		_	_
Amounts payable under securities lending	571		(571)		_		571		_		_		_	_
Separate accounts liabilities - derivatives	1		1		1		_		_		_		_	
Separate accounts liabilities - derivative collateral	_		_		_		_		_		_		_	
Separate accounts liabilities	 1		1		1								_	
Total liabilities	\$ 49,494	\$	49,800 \$	5	1 \$		2,496 \$	\$	46,997	\$		\$	_	

<sup>&</sup>lt;sup>1</sup> Excludes investments accounted for under the equity method.

### Bonds

The fair value of bonds is determined by considering one of four primary sources: (1) security pricing is applied using a hierarchy approach whereby publicly available prices are first sought from nationally recognized third-party pricing services, (2) securities are priced using a matrix-based pricing methodology, which uses spreads derived from third-party benchmark bond indices, (3) securities are priced using an internal pricing model or methodology, and (4) securities are submitted to independent brokers for prices.

The pricing service generally uses an income-based valuation approach by using a discounted cash-flow model or it may also use a market approach by looking at recent trades of a specific security to determine fair value or a combination of the two. Typical inputs used by these

pricing services include, but are not limited to: benchmark yields, reported trades, issuer spreads, bids, offers, benchmark securities, estimated cash flows and prepayment speeds.

Independent pricing vendors do not supply prices for private placement bonds. These securities are primarily priced using a market approach such as a matrix-based pricing methodology, which uses spreads derived from third-party benchmark bond indices. Any private securities that cannot be priced using this methodology, are priced using an internally developed model based upon assigned comparable public issues adjusted for liquidity, maturity and rating, or are priced based on internal calculations. The Company assigns a credit rating based upon internal analysis.

Prices from pricing services and broker quotes are validated on an ongoing basis to ensure the adequacy and reliability of the fair value measurement. The Company performs both quantitative and qualitative analysis of the prices including initial and ongoing review of third-party pricing methodologies, back testing of recent trades, and a thorough review of pricing trends and statistics.

Included in bonds is an affiliated bond from Madison Capital Funding LLC ("MCF"). The affiliated bond from MCF had a carrying value of \$3,445 million and a fair value of \$3,454 million at June 30, 2025. The fair value of this security is calculated internally and may include inputs that may not be observable. Therefore, this security is classified as Level 3.

### Preferred stocks

Preferred stocks valued using prices from third-party pricing services generally use a discounted cash flow model or a market approach to arrive at the security's fair value and are classified as Level 2. Preferred stocks classified as Level 3 are valued based on internal valuations where significant inputs are deemed to be unobservable.

#### Common stocks

These securities are comprised of exchange traded U.S. and foreign common stock and mutual funds. The fair value of these securities is primarily based on unadjusted quoted prices in active markets that are readily and regularly available and are classified as Level 1. Common stocks that do not trade in an active market and are valued based on prices obtained from independent pricing vendors using unadjusted quoted prices in active markets for similar securities that are readily and regularly available are classified as level 2. Common stocks priced through an internal valuation where significant inputs are deemed to be unobservable, including securities issued by government organizations where fair value is fixed, are classified as Level 3.

### Mortgage loans

The estimated fair value of mortgage loans is determined using an income approach, based upon the present value of the expected cash flows discounted at an interpolated treasury yield plus a spread. The spread is based on management's judgment and assumptions, which takes into account matters such as property type, loan-to-value ratio loan to value and remaining term of each loan, etc. The spread is a significant component of the pricing inputs, and therefore, these investments are classified as Level 3.

### Cash, cash equivalents, short-term investments and investment income due and accrued

Cash on hand and money market mutual funds are classified as Level 1. Cash overdrafts (i.e. outstanding checks) are classified as Level 2. Due to the short-term maturities of cash equivalents, short term investments, and investment income due and accrued, carrying value approximates fair value and is classified as Level 2.

### Derivatives (including separate accounts liabilities)

The fair value of derivative instruments is generally derived using valuation models that use an income approach, except for derivatives that are exchange-traded, which are valued using quoted prices in an active market. Where valuation models are used, the selection of a particular model depends upon the contractual terms of, and specific risks inherent in the instrument, as well as the availability of pricing information in the market. The Company generally uses similar models to value similar instruments. Valuation model inputs include contractual terms, yield curves, foreign exchange rates, equity prices, credit curves, measures of volatility and other factors.

### Other invested assets

Other invested assets are principally comprised of low-income housing tax credits ("LIHTC") investments and surplus notes, affiliated loans, preferred units of a limited partnership, and certain other investments with characteristics of debt. Surplus Notes are valued using prices from third-party pricing services that generally use a discounted cash-flow model or a market approach to arrive at the security's fair value and are classified as Level 2. The fair value of the affiliated loans and the LIHTC investments is derived using an income valuation approach, which is based on a discounted cash flow calculation using a discount rate that is determined internally. These investments are classified as Level 3 because the discount rate used is based on management's judgment and assumptions. The fair value of investments with debt characteristics and the fair value of the majority of residual tranches of securitizations is derived using an income valuation approach, which is based on a discounted cash flow calculation that may or may not use observable inputs and therefore is classified as Level 3. The fair value of the preferred units in a limited partnership is derived internally based on market comparable preferred units and recent transactions by the limited partnership. The valuation technique used required inputs that were both unobservable and significant and therefore classified as Level 3. Capital notes and non-bond debt securities were reclassed from bonds to other invested assets at 1/1/2025 for failing to meet the new definition of a bond under the principles-based bond definition.

### Derivatives - collateral (including separate accounts liabilities collateral)

The carrying value of these instruments approximates fair value since these assets and liabilities are generally short-term in nature and are classified as Level 2.

### Separate accounts assets (including separate account assets - collateral)

Assets within the separate accounts are primarily invested in bonds and common stock. The fair value of investments in the separate accounts is calculated using the same procedures as are used for bonds and common stocks in the general account.

The separate accounts also invest in limited partnerships and hedge fund investments. The fair value of such partnerships is determined by reference to the limited partnership's NAV. The valuation of the hedge funds is based upon the hedge funds' latest financial statements adjusted for cash activity since that date and estimates of market valuations.

### **Deposit fund contracts**

For funding agreements backing medium term notes, fair values are based on available market prices for the notes. For other funding agreements and annuities certain liabilities, fair values are estimated using discounted cash flow calculations based on interest rates currently being offered for similar contracts with maturities consistent with those remaining for the contracts being valued. For all other deposit funds, the fair value is estimated to be equal to the account value since they can be withdrawn at anytime and without prior notice.

### Premiums paid in advance

For premiums paid in advance, the carrying value of the liability approximates fair value.

### Amounts payable under securities lending

Amounts due under securities lending consists of cash collateral received under securities lending agreements. Due to the short-term nature of the transactions, the carrying value approximates fair value.

- **C.** If it is not practicable for an entity to estimate the fair value of that financial instrument or a class of financial instruments, the following shall be disclosed:
  - (1) (2) Not applicable.

**D.** The following table provides additional information for investments that are measured using NAV as a practical expedient to estimate fair value, as allowed under authoritative guidance, for investments that meet specified criteria (in millions):

June 30, 2025											
Category of Investment	Investment Strategy		Fair Value Determined Using NAV		Unfunded Commitments	Redemption Frequency	Redemption Notice Period				
Hedge fund	Long/short equity, futures, options, foreign exchange arbitrage	\$	21	\$	s –	Annual, Semi- Annual, Quarterly, Monthly	30-90 days (Assets subject to lock-up periods)				
Hedge fund	Distressed securities, multi- strategy		1		_	Semi-Annual, Quarterly	60-90 days (Assets subject to lock-up periods)				
Private equity	Leverage buyout, mezzanine financing, distressed securities		1,140	_	198	N/A	N/A				
		•	4 400								

# Note 3 - Subsequent Events

At August 12, 2025, the date the financial statements were available to be issued, there have been no events occurring subsequent to the close of the Company's books or accounts which would have a material effect on the financial condition of the Company.